SCHEMBL700858

SCHEMBL700858

O=C(O)C(O)C(O)C(=O)Nc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 11/20 0.59
MEN1 O00255 10/20 0.59
NPC1 O15118 3/20 0.54
RAB9A P51151 2/20 0.54
MITF O75030 1/20 0.54
POLB P06746 1/20 0.54
GAA P10253 1/20 0.54
TGM2 P21980 1/20 0.51
MAPT P10636 6/20 0.51
LMNA P02545 3/20 0.51
ALDH1A1 P00352 3/20 0.51
NPSR1 Q6W5P4 2/20 0.51
MAPK1 P28482 2/20 0.50
NAMPT P43490 1/20 0.50
MYOC Q99972 1/20 0.50
HPGD P15428 1/20 0.50
ALOX12 P18054 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.49
HTT P42858 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11763994 1.00 KMT2A (0.59) KMT2AMEN1NPC1RAB9AMITF
Cadaverine Tartrate SCHEMBL28015424 0.84 TDP1 (0.59) KMT2AMEN1POLBMAPTLMNA
SCHEMBL29111851 0.80 KMT2A (0.62) KMT2AMEN1NPC1RAB9AMITF
SCHEMBL29111764 0.80 KMT2A (0.62) KMT2AMEN1NPC1RAB9AMITF
SCHEMBL29111760 0.80 KMT2A (0.62) KMT2AMEN1NPC1RAB9AMITF
SCHEMBL29206349 0.78 MEN1 (0.59) KMT2AMEN1NPC1RAB9AMITF
SCHEMBL29206352 0.78 MEN1 (0.59) KMT2AMEN1NPC1RAB9AMITF
SCHEMBL29194039 0.78 MEN1 (0.65) KMT2AMEN1NPC1RAB9AMITF
SCHEMBL6918119 0.78 MAPT (0.70) KMT2AMEN1NPC1RAB9APOLB
SCHEMBL701232 0.78 KMT2A (0.54) KMT2AMEN1NPC1RAB9APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260015355-A1 METHOD FOR THE PREPARATION OF (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1-6-NAPHTHYRIDINE-3-CARBOX-AMIDE BY RACEMATE SEPARATION BY MEANS OF DIASTEREOMERIC TARTARIC ACID ESTERS BAYER AKTIENGESELLSCHAFT (DE) 2026-01-15 US disclosed
US-20250340553-A1 METHOD FOR THE PREPARATION OF (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1-6-NAPHTHYRIDINE-3-CARBOX-AMIDE BY RACEMATE SEPARATION BY MEANS OF DIASTEREOMERIC TARTARIC ACID ESTERS BAYER AKTIENGESELLSCHAFT (DE) 2025-11-06 US disclosed
US-12448381-B1 Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carbox-amide by racemate separation by means of diastereomeric tartaric acid esters BAYER AKTIENGESELLSCHAFT (DE) 2025-10-21 US disclosed
US-20250270204-A1 PROCESS FOR THE PREPARATION OF 2-CYANOETHYL (4S)-4-(4-CYANO-2-METHOXY-PHENYL)-5-HYDROXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDIN-3-CARBOXYLATE BY RACEMATE SEPARATION BY MEANS OF DIASTEREOMERIC TARTARIC ACID ESTERS BAYER AKTIENGESELLSCHAFT (DE) 2025-08-28 US disclosed
US-20240376103-A1 METHOD FOR THE PREPARATION OF (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1-6-NAPHTHYRIDINE-3-CARBOX-AMIDE BY RACEMATE SEPARATION BY MEANS OF DIASTEREOMERIC TARTARIC ACID ESTERS BAYER AKTIENGESELLSCHAFT (DE) 2024-11-14 US disclosed
US-12054481-B2 Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carbox-amide by racemate separation by means of diastereomeric tartaric acid esters BAYER AKTIENGESELLSCHAFT (DE) 2024-08-06 US disclosed
US-20240199599-A1 PROCESS FOR THE PREPARATION OF 2-CYANOETHYL (4S)-4-(4-CYANO-2-METHOXY-PHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXYLATE BY RESOLUTION OF RACEMATES BY MEANS OF DIASTEREOMERIC TARTARIC ACID ESTERS BAYER AKTIENGESELLSCHAFT (DE) 2024-06-20 US disclosed
US-20210163474-A1 METHOD FOR THE PREPARATION OF (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1-6-NAPHTHYRIDINE-3-CARBOX-AMIDE BY RACEMATE SEPARATION BY MEANS OF DIASTEREOMERIC TARTARIC ACID ESTERS BAYER AKTIENGESELLSCHAFT (DE) 2021-06-03 US disclosed
EP-3560922-A1 PROCESS FOR PREPARATION OF (4S) - 4- (4-CYANO-2-METHOXYPHENYL) -5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXAMIDE BY RACEMATE RESOUTION THROUGH DIASTEREOMERIC TARTARIC ACID Bayer Aktiengesellschaft (DE) 2019-10-30 EP disclosed
EP-2423211-B1 PROCESSES FOR PRODUCING (1S,6S)- OR (1R,6R)-CIS-2,8-DIAZABICYCLO[4.3.0]NONANE AND INTERMEDIATE THEREOF KANEKA CORP (JP) 2014-04-16 EP disclosed
EP-2423211-A1 PROCESSES FOR PRODUCING (1S,6S)- OR (1R,6R)-CIS-2,8-DIAZABICYCLO[4.3.0]NONANE AND INTERMEDIATE THEREOF Kaneka Corporation (JP) 2012-02-29 EP disclosed
US-8063251-B2 Process for the preparation of optically pure R (−) salbutamol and its pharmaceutically acceptable salts AARTI HEALTHCARE LIMITED (IN) 2011-11-22 US disclosed
US-20100204516-A1 PROCESS FOR THE PREPARATION OF OPTICALLY PURE R (-) SALBUTAMOL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS AARTI HEALTHCARE LIMITED (IN) 2010-08-12 US disclosed
EP-1091958-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2001-04-18 EP disclosed
WO-2000001692-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2000-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204516-A1 PROCESS FOR THE PREPARATION OF OPTICALLY PURE R (-) SALBUTAMOL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS FFAR4, ADRB1, NR1H4 KMT2A 4351/4885MEN1 4547/4885NPC1 2113/4885
US-20250270204-A1 PROCESS FOR THE PREPARATION OF 2-CYANOETHYL (4S)-4-(4-CYANO-2-METHOXY-PHENYL)-5-HYDROXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDIN-3-CARBOXYLATE BY RACEMATE SEPARATION BY MEANS OF DIASTEREOMERIC TARTARIC ACID ESTERS MVD, CYP24A1, CYP4B1 KMT2A 2418/4885MEN1 3622/4885NPC1 771/4885
US-20250340553-A1 METHOD FOR THE PREPARATION OF (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1-6-NAPHTHYRIDINE-3-CARBOX-AMIDE BY RACEMATE SEPARATION BY MEANS OF DIASTEREOMERIC TARTARIC ACID ESTERS SRD5A1, NR4A1, SRD5A2 KMT2A 2927/4885MEN1 4336/4885NPC1 1765/4885
US-20260015355-A1 METHOD FOR THE PREPARATION OF (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1-6-NAPHTHYRIDINE-3-CARBOX-AMIDE BY RACEMATE SEPARATION BY MEANS OF DIASTEREOMERIC TARTARIC ACID ESTERS NR3C2, SRD5A1, SRD5A2 KMT2A 4261/4885MEN1 3596/4885NPC1 1479/4885
US-20210163474-A1 METHOD FOR THE PREPARATION OF (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1-6-NAPHTHYRIDINE-3-CARBOX-AMIDE BY RACEMATE SEPARATION BY MEANS OF DIASTEREOMERIC TARTARIC ACID ESTERS SRD5A1, NR4A1, SRD5A2 KMT2A 2927/4885MEN1 4336/4885NPC1 1765/4885
US-20240376103-A1 METHOD FOR THE PREPARATION OF (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1-6-NAPHTHYRIDINE-3-CARBOX-AMIDE BY RACEMATE SEPARATION BY MEANS OF DIASTEREOMERIC TARTARIC ACID ESTERS SRD5A1, NR4A1, SRD5A2 KMT2A 2927/4885MEN1 4336/4885NPC1 1765/4885
US-12448381-B1 Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carbox-amide by racemate separation by means of diastereomeric tartaric acid esters SRD5A1, NR4A1, SRD5A2 KMT2A 2927/4885MEN1 4336/4885NPC1 1765/4885
US-12054481-B2 Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carbox-amide by racemate separation by means of diastereomeric tartaric acid esters SRD5A1, NR4A1, SRD5A2 KMT2A 2927/4885MEN1 4336/4885NPC1 1765/4885
US-20240199599-A1 PROCESS FOR THE PREPARATION OF 2-CYANOETHYL (4S)-4-(4-CYANO-2-METHOXY-PHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXYLATE BY RESOLUTION OF RACEMATES BY MEANS OF DIASTEREOMERIC TARTARIC ACID ESTERS MVD, VARS1, CYP4B1 KMT2A 3248/4885MEN1 3529/4885NPC1 628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.